Lobby organisation
argenx
Business / industry · Health & pharma · HQ: Belgium · website · Transparency Register entry
As of 9 September 2026, argenx appears in 4 declared MEP meetings (4 different MEPs), most often with European People's Party.
In their own words
“We are a commercial-stage, global, fully-integrated biopharma company developing a deep pipeline of differentiated therapies for the treatment of severe autoimmune diseases. By combining our suite of antibody engineering technologies with the disease biology expertise of our research collaborators, we aim to translate immunology breakthroughs into a pipeline of novel antibody-based medicines through our discovery engine, the IIP. We have…”
Stated goals from the organisation's own Transparency Register filing.
Who they meet, and when
Which groups they meet
Share of this organisation's 4 declared meetings, by the meeting MEP's political group.
Meetings by year
Declared meetings per calendar year, 2024–2026. Bar length is relative to its busiest year (2 in 2026).
Group is each MEP's current political group, not necessarily the one they sat with at the time. Shares are rounded to whole percent.
The MEPs they meet most
The 4 most recent declared meetings
| Date | MEP | Subject |
|---|---|---|
| 2 Jul 2026 | Sirpa Pietikäinen | Women's health |
| 13 May 2026 | Wouter Beke | EU Biotech Act I |
| 20 Feb 2025 | Tomislav Sokol | Health policy |
| 31 Jan 2024 | Nicolás González Casares | Pharma legislation |
Meeting an MEP is a normal part of democratic life; the record is shown so anyone can see it.